Good evening :)
Place Order
Add to Watchlist

Aurobindo Pharma Ltd

AUROPHARMA

Aurobindo Pharma Ltd

AUROPHARMA
Health CarePharmaceuticals
MidcapWith a market cap of ₹81,135 cr, stock is ranked 123
Moderate RiskStock is 2.07x as volatile as Nifty
1,394.850.15% (-2.10)
1,394.850.15% (-2.10)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹81,135 cr, stock is ranked 123
Moderate RiskStock is 2.07x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹81,135 cr, stock is ranked 123
Moderate RiskStock is 2.07x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
23.042.720.32%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.316.550.51%

Forecast & Ratings

Detailed Forecast 
69%
Analysts have suggested that investors can buy this stock

from 26 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 8.43%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 8.99% to 7.84%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 6.06%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue13,999.9015,030.4516,568.1519,721.5723,290.3828,404.9723,891.8725,145.9729,559.2530,425.32
Raw Materialssubtract6,254.986,743.467,235.269,388.199,837.0910,632.689,323.6011,702.9413,549.0723,589.99
Power & Fuel Costsubtract419.26437.14470.95556.79587.68589.28626.86842.63826.03
Employee Costsubtract1,542.621,767.762,130.842,584.873,219.183,535.023,450.923,522.253,922.94
Selling & Administrative Expensessubtract1,684.891,969.342,270.452,363.933,162.203,638.423,332.283,705.323,973.53
Operating & Other expensessubtract704.78557.56583.78805.891,469.351,536.102,610.311,375.271,096.32
Depreciation/Amortizationsubtract392.37427.63557.97667.95966.711,055.391,126.521,244.581,521.661,599.28
Interest & Other Itemssubtract256.7066.7277.72262.60305.1374.4948.64140.48289.71344.20
Taxes & Other Itemssubtract719.21759.18818.01726.62897.902,008.75724.59685.001,207.021,370.41
EPS34.6439.3141.3640.3648.5691.0545.2032.9054.1560.10
DPS2.502.502.502.503.004.009.007.504.504.50
Payout ratio0.070.060.060.060.060.040.200.230.080.07

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 9PDF
Nov 8PDF
Aug 12PDF
FY 2023

Annual report

PDF

Investor Presentation

May 27PDF
Feb 9PDF
Nov 12PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 12PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aurobindo Pharma Ltd25.572.720.32%
Sun Pharmaceutical Industries Ltd45.196.450.75%
Cipla Ltd31.374.820.81%
Mankind Pharma Ltd56.8511.36—

Price Comparison

Compare AUROPHARMA with any stock or ETF
Compare AUROPHARMA with any stock or ETF
AUROPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding51.82%18.53%6.60%16.59%6.46%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep24.13%22.45%20.72%18.02%16.73%16.59%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Aurobindo Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan

Growth
2.3314%2.45%0.26%12/79 (+4)
Quant Mid Cap Fund - Growth - Direct Plan

Growth
1.0668%9.18%0.86%7/43 (-1)
Mirae Asset Large & Midcap Fund - Growth - Direct Plan

Growth
0.7597%1.53%0.10%14/104 (+6)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

AUROPHARMA has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.32%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.23 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 20, 2024

Interim 2
Interim 2 | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Feb 20, 2024

Cash Dividend

Ex DateEx DateNov 20, 2023

Interim 1
Interim 1 | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Nov 20, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Interim 1
Interim 1 | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Feb 17, 2023

Cash Dividend

Ex DateEx DateJun 6, 2022

Interim 4
Interim 4 | Div/Share: ₹4.50

Dividend/Share

₹4.50

Ex DateEx Date

Jun 6, 2022

Cash Dividend

Ex DateEx DateFeb 18, 2022

Interim 3
Interim 3 | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Feb 18, 2022

News & Opinions
Corporate
Aurobindo Pharma to table results

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Aurobindo Pharma completes acquisition of balance 49% stake in GLS Pharma

Aurobindo Pharma has completed the acquisition of balance 49% stake in its subsidiary, GLS Pharma on 25 October 2024. With this transaction, GLS Pharma has become a wholly owned subsidiary of the Company.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Aurobindo Pharma Ltd spurts 1.19%, up for fifth straight session

Aurobindo Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 1509.05, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 25134.8. The Sensex is at 82005.72, up 0.45%. Aurobindo Pharma Ltd has slipped around 0.62% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 2.13% in last one month and is currently quoting at 23307.95, up 1.91% on the day. The volume in the stock stood at 3.63 lakh shares today, compared to the daily average of 13.57 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1519, up 1.41% on the day. Aurobindo Pharma Ltd is up 67.5% in last one year as compared to a 27.65% spurt in NIFTY and a 57.23% spurt in the Nifty Pharma index.The PE of the stock is 45.69 based on TTM earnings ending June 24.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Aurobindo Pharma's step down subsidiary to divest its entire stake in JV 'Novagen'

Aurogen South Africa (Aurogen), a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Novabee Proprietary, to sell and dispose of the entire 50% shares held by Aurogen in Novagen. After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Aurobindo Pharma's step down subsidiary to divest its entire stake in a South African JV

Aurogen South Africa, (Aurogen) a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary). Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Auro Pharma gets USFDA nod for urinary tract infections drug.

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and company. The product will be launched in Q3FY25. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. The drug maker now has a total of 523 ANDA approvals (506 Final approvals and 17 tentative approvals) from USFDA. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 79.5% jump in consolidated net profit to Rs 908.75 crore on a 17.1% rise in revenue from operations to Rs 7,580.15 crore in Q4 FY24 over Q4 FY23. Shares of Aurobindo Pharma rose 0.83% to Rs 1,450.55 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Aurobindo Pharma receives USFDA approval for Cephalexin Tablets

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cephalexin Tablets USP, 250 mg and 500 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and Company. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity. The product is expected to be launched in Q3FY25. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Aurobindo Pharma slides after arm's Telangana facility gets 10 USFDA observations

The USFDA conducted inspection from 23 September to 27 September 2024.The inspection was closed with 10 observations. The firm stated that the observations are of procedural in nature and will be responded to within the stipulated time. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 61.1% surge in consolidated net profit to Rs 919.22 crore on a 9.8% rise in revenue from operations to Rs 7,457.65 crore in Q1 FY25 over Q1 FY24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
USFDA conducts inspection of Apitoria Pharma's unit II

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam Village IDA, Jinnaram Mandal, Sanga Reddy District, Telangana from 23-27 September 2024. The inspection closed with 10 observations. The observations are of procedural in nature and will be responded to within the stipulated time.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Auro Pharma arm gets EIR from USFDA for AP facility

The United States Food and Drug Administration (USFDA) had conducted a pre-approval inspection (PAI) of the new injectable facility of Eugia Steriles, situated at Parawada Mandal, Anakapalli District in Andhra Pradesh, from 28 March 2024 to 5 April 2024. The unit has now received the EIR and the inspection is closed. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 61.1% surge in consolidated net profit to Rs 919.22 crore on a 9.8% rise in revenue from operations to Rs 7,457.65 crore in Q1 FY25 over Q1 FY24. Shares of Aurobindo Pharma fell 0.62% to currently trade at Rs 1,542.40 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live